Senator has questions on Amgen anemia drug rebates
Reuters, April 4, 2008
Sen. Charles Grassley is questioning Amgen Inc. regarding allegations that some doctors received higher rebates on purchases of the company's anti-anemia drug Aranesp. In a statement, Grassley said there were concerns doctors were profiting by getting reimbursements from the government and private insurers that were higher than their actual cost for Aranesp. The drug is currently under scrutiny for safety concerns.
- Will More Pioneer ACOs Defect?
- Charity HealthCare Conundrum Brewing Among Providers
- MU Final Rule Disappoints Some CIOs
- Evidence-Based Practice and Nursing Research: Avoiding Confusion
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- CNO Leads $1M Charge for New Scrubs, Uniforms
- mHealth Tackles Readmissions
- Acute Kidney Injury Gets New Focus
- 'Terrible' Patient Becomes Dedicated Nurse